Veeva Systems Inc (VEEV) Quote

$VEEV: Helluva report.......... now $276

They killed the quarterly earnings


GO $VEEV

*********************************************************************


Veeva Systems Inc (VEEV) Q1 2026 Earnings Call Highlights: Surpassing Revenue Goals and ...

GuruFocus News
Thu, May 29, 2025 at 3:05 AM EDT 4 min read

In This Article:
VEEV
+18.39%

Total Revenue: $759 million for the quarter.

Non-GAAP Operating Margin: 46%.

Revenue Run Rate Goal: Achieved $3 billion for calendar 2025.

Release Date: May 28, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points
Veeva Systems Inc (NYSE:VEEV) reported total revenue of $759 million, surpassing their guidance.

The company achieved a non-GAAP operating margin of 46%, indicating strong operational efficiency.

Veeva AI is a major initiative that is off to a good start, with potential positive impacts on the life sciences industry.

The company has successfully onboarded over 80 customers to Vault CRM, with plans to reach 200 customers within a year.

Crossix, a part of Veeva's commercial segment, outperformed expectations and is growing at more than 30% year-over-year.

Negative Points
The macroeconomic environment is uncertain, largely due to dynamics in the US administration, which could impact future performance.

Some customers prefer custom projects, which may lead to decisions against migrating to Veeva's solutions.

The company acknowledges potential funding issues in the small biopharma market due to macroeconomic uncertainties.

Veeva's horizontal CRM initiative is still in the early stages, with many details yet to be determined.

There is a risk of conservatism in large pharma due to macroeconomic uncertainties, which could delay projects.

Q & A Highlights
Warning! GuruFocus has detected 4 Warning Sign with VEEV.

Q: Can you provide insights into the migration of 200 customers to Vault CRM and the factors influencing their decisions? A: Paul Shawah, EVP, Strategy: Vault CRM is performing well, with over 80 customers live today and on track to reach 200 in a year. The migrations are driven by Vault CRM's superior features, including our AI strategy and integration of sales, marketing, and medical functions. Some customers prefer custom projects, but we expect to retain the majority.

Q: How is the macro environment affecting Veeva's business, particularly in discretionary revenue areas like services? A: Peter Gassner, CEO: Despite macro uncertainties, we haven't seen a material impact on our results or pipeline. Smaller biopharma might face funding issues, but areas like Crossix, which offer quick ROI, are less likely to be affected.

Q: Can you elaborate on Veeva's strategy for entering the horizontal CRM market? A: Peter Gassner, CEO: We're excited about horizontal CRM, focusing initially on large enterprises. We aim to differentiate through innovation and our public benefit corporation model. We hope to have our first customers by year-end, emphasizing customer success and product excellence.


Story Continues
Terms and Privacy Policy
Privacy Dashboard
Insider Monkey
Zscaler, Inc. (ZS) Expands AI Security Capabilities by Acquiring Red Canary Deal
Venkatesh
Wed, May 28, 2025 at 9:38 PM EDT 2 min read

In This Article:
StockStory Top Pick
ZS
-0.61%

Zscaler, Inc. (NASDAQ:ZS) announced on May 27, 2025, its definitive agreement to acquire Red Canary, a leading provider of Managed Detection and Response (MDR) solutions. The move aims at strengthening the company’s AI-powered security by incorporating Red Canary’s automation-led threat detection capabilities into its Zero Trust Exchange platform.

Zscaler, Inc. (ZS) Expands AI Security Capabilities by Acquiring Red Canary Deal
Zscaler, Inc. (ZS) Expands AI Security Capabilities by Acquiring Red Canary Deal
An employee standing in front of a large data center, looking toward the future of cloud security.

Through the acquisition, Zscaler, Inc. (NASDAQ:ZS) aims to merge its cloud-scale data fabric and global threat intelligence with Red Canary’s decade-long expertise in streamlining threat investigation.

Jay Chaudhry, CEO of Zscaler, Inc. (NASDAQ:ZS), made the following comment:

“The proposed acquisition of Red Canary is a natural expansion of our capabilities into managed detection and response and threat intelligence to accelerate our vision of AI-powered SOC of the future. By integrating Red Canary with Zscaler, we will deliver to our customers the power of a fully integrated Zero Trust platform and AI-powered security operations.”

The company has also recently invested in tools like Risk360 and Exposure Management, signaling Zscaler, Inc. (NASDAQ:ZS)’s intent to shift toward a fully integrated and intelligent Security Operations Center.

Investor sentiment remains strong for Zscaler, Inc. (NASDAQ:ZS). Shortly after the deal was revealed, Cantor Fitzgerald raised its price target from $250 to $275 while maintaining an Overweight rating. Analysts from Stephens & Co. also reiterated an Overweight stance, stressing their confidence in the company’s growing role in enterprise cybersecurity.

While we acknowledge the potential of ZS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZS and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds

Disclosure: None.

Terms and Privacy Policy
Privacy Dashboard
Zacks
Veeva Systems (VEEV) Q1 Earnings and

VEEV reports May 28

Vee should be looking at Anavex Life Sciences to help with multiple drug candidates. Just say'n

$25 coming!!!

Thinking this fills the 300.00 gap maybe even down to 295. Will buy dec 17 300 call then. Maybe a Jan 310. Not sure yet!

Bears are really putting up a fight here

Yea they do, but sellers have been relentless for the past week or so

Thank you!
I think they report tomorrow after the close. Making progress on the non pharmaceutical verticals.

High of day, it’s taking longer than i expected to make a new one. Tempted to just take my profits here and move on

“HOD” means?

New HOD coming in the next 30 min most likely. Buy buy buy

Reversal confirmed, buy buy buy

News: $VEEV New Veeva OpenData Explorer Provides Online Access to Real-time HCP, HCO, Affiliation, and Compliance Data

Veeva also announces open API making it easier to integrate customer data with third-party applications and services Open approach gives industry flexibility, choice to leverage their customer data without restrictions Life sciences companies want the freedom to use their customer...

Find out more VEEV - New Veeva OpenData Explorer Provides Online Access to Real-time HCP, HCO, Affiliation, and Compliance Data

News: $VEEV Better Buy: Salesforce.com vs. Veeva Systems

Salesforce.com  (NYSE: CRM) and  Veeva Systems  (NYSE: VEEV) share a lot in common, and it goes far beyond the fact that these two have pioneered the software-as-a-service (SaaS) business model.  Peter Gassner -- Veeva's founder and CEO -- was an executive at Salesfor...

Read the whole news VEEV - Better Buy: Salesforce.com vs. Veeva Systems

After strong quarter Merrill and Keybanc increase target prices to $190. Move into cosmetics, consumer products and chemical industry noted. New conference Oct 8 in Chicago will feature these three new customer targets with 500 + prospects attending

$VEEV TO MUCH RISK INTO EARNINGS, LOOKS LIKE A SHORT

The cloud kings are having real trouble this earnings season, regardless of how good the earnings or outlook is, post earnings selling has hindered any progress. We think NYSE:VEEV is vulnerable as earnings approach , having climbed 80% in 5 months the stock is already overextended, with bearish divergence on the indicators.The stock needs a healthy pullback and it will not have long to wait to get it.

News: $VEEV VEEV Stock Hits Fresh Highs: Robust Q1 Numbers and Earnings Outlook

VEEV stock is the notable gainer on Thursday after Veeva Systems Inc (NYSE:VEEV) reported much better than estimated first-quarter results. Late Wednesday, the company posted its earnings for Q1 2019, and the numbers are solid. In addition to that, Veeva also raised its projections for ...

Find out more https://marketwirenews.com/news-releases/veev-stock-hits-fresh-highs-robust-q1-numbers-and-earnings-outlook-8271832.html

One strategy would be for CRM to acquire VEEV at $100plus and accelerate cross selling into industrial, consumer products and quality control market sectors.

CML?

MISSION ACCOMPLISHED

CONGRAT$

$50 is my target here

Veeva ready to roll got my CML alert

http://ih.advfn.com/p.php?pid=nmona&article=72242523

"Veeva’s industry cloud solutions gain momentum as companies unify business processes for faster time to market and greater compliance

As life sciences companies continue their transition from legacy on-premises and horizontal cloud software to industry-specific cloud applications, Veeva Systems (NYSE:VEEV) is strengthening its position as a fast-growing, strategic vendor in the industry across its most critical functions. According to Gartner, Veeva’s extensive cloud-based multitenant software solution set across research and development (R&D) and commercial is building the company into a strategic-level vendor for global pharma and biotech clients.1

Increased complexity in life sciences – from global stakeholder ecosystems to regulatory requirements – is driving organizations to streamline operations to be more efficient and agile. This is in an effort to accelerate innovation and get products to market faster and more effectively on a global scale. Organizations are implementing new cloud approaches to improve collaboration and provide smarter ways of working.

As a result, the industry is increasingly relying on Veeva’s applications to streamline their global business operations, with 35 of the top 50 pharmaceutical companies using Veeva Vault to unify their processes and content on a single platform in the areas of commercial, clinical, regulatory, quality and medical.2 Customers are turning to Veeva to help them improve overall business agility, compliance, and risk mitigation.

Over the next five years, Gartner expects migration to multichannel marketing to strengthen and grow within pharma and recognized Veeva as one of only two vendors to offer complete CRM products, support, and services across most of the globe.3 Veeva is in the market share leadership position of the pharma CRM vendor landscape.4

According to IDC Health Insights, Veeva’s continued momentum in the sales and marketing space has strengthened its leadership in the industry.5 “Veeva has leveraged its strong position in the life science CRM space to provide an optimized omni-channel solution for its customers, with access to its cloud-based content management, master data management, and system-wide customer data,” according to the report.

In R&D, Vault Clinical, Vault RIM, and Vault Quality are helping companies streamline their end-to-end clinical trial processes, respond faster to business changes and health authority requests, and integrate their quality processes and content. Within commercial operations, Veeva Commercial Cloud is improving how life sciences companies bring together customer data, compliant content, and multichannel engagement to market and sell more effectively. While Veeva Medical Solutions help organizations discover, target, and engage the right opinion leaders.

“There is a significant shift occurring in the industry to cloud applications that streamline and unify business processes,” said Paul Shawah, vice president of product marketing at Veeva. “Our focus on industry-specific applications is helping our customers transform their R&D, commercial, and medical operations to support faster product launches and quickly adopt new business models. Industry analysts validate that we are gaining momentum as a strategic partner to the industry.”...."

"1 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
2 As of April 30, 2016.
3 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
4 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
5 Alan S. Louie, Ph.D., Michael Townsend, Eric Newmark (IDC Health Insights: June 2016), Business Strategy: Top Software Vendors in the Life Science Industry, 2015"

VEEV (President) Matthew Wallach just cashed in shares for $2.4M (Holiday Ca$h)


Matt is cash flush for the Holidaze


GOOOO000 MATT

$VEEV recent news/filings

bullish

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$VEEV DD Notes ~ http://www.ddnotesmaker.com/VEEV

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=VEEV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=VEEV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=VEEV+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/news - http://finance.yahoo.com/q/h?s=VEEV+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/VEEV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=VEEV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/VEEV
DTCC (dtcc.com): http://search2.dtcc.com/?q=Apple%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Apple%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Apple%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.apple.com/pr
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.apple.com/pr#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.apple.com/pr

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/VEEV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000320193&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=VEEV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=VEEV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=VEEV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=VEEV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=VEEV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=VEEV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=VEEV+VEEVh+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/VEEV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=VEEV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/VEEV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=VEEV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/VEEV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/VEEV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/VEEV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=VEEV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=VEEV
StockTwits (stocktwits.com): http://stocktwits.com/symbol/VEEV

$VEEV DD Notes ~ http://www.ddnotesmaker.com/VEEV

$VEEV Up 10.85%, crossovers onMACD, PMO and RSI. May have another 15 % possible gain. Im jumping in before closing

T Rowe Price 15% stake

The Motley Fool is highly recommending VEEV

$450M in assets
144M diluted share count

BlackRock owns 12% at around $200M.

$VEEV DD Notes ~ http://www.ddnotesmaker.com/VEEV

bullish

$VEEV charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$VEEV company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/VEEV/company-info
Ticker: $VEEV
OTC Market Place: Not Available



## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=VEEV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=VEEV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=VEEV+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/news - http://finance.yahoo.com/q/h?s=VEEV+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/VEEV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=VEEV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/VEEV

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/VEEV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=VEEV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=VEEV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=VEEV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=VEEV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=VEEV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=VEEV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=VEEV+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/VEEV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=VEEV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/VEEV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=VEEV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/VEEV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/VEEV/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/VEEV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/VEEV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/VEEV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=VEEV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=VEEV



$VEEV DD Notes ~ http://www.ddnotesmaker.com/VEEV

WILLIAM BLAIR INITIATES COVERAGE ON VEEVA SYSTEMS AT OUTPERFORM
S&P Capital IQ
SNPMarketScopeViewsNews2014-09-22 07:03:24.000VEEVVEEVA SYSTEMS INC.Acquire MediaWILLIAM BLAIR INITIATES COVERAGE ON VEEVA SYSTEMS AT OUTPERFORM William Blair initiates coverage on Veeva Systems (NYSE: VEEV) with a Outperform rating. View More Analyst Ratings for VEEVView the Latest Analyst Ratings 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Acquire Media|US;VEEV|234201107|US|68430492

It's happening! Up 20% on Friday and it ain't over. Is there anybody out there? lol.

5 Stocks Set to Soar on Bullish Earnings

Veeva Systems 08/26/14

My first earnings short-squeeze play is cloud-based software solutions provider Veeva Systems (VEEV) , which is set to release numbers on Thursday after the market close. Wall Street analysts, on average, expect Veeva Systems to report revenue of $69.28 million on earnings of 7 cents per share.

The current short interest as a percentage of the float for Veeva Systems is extremely high at 32.4%. That means that out of the 37.24 million shares in the tradable float, 12.09 million shares are sold short by the bears. This is a huge short interest on a stock with a relatively low tradable float. Any bullish earnings news could easily set off a monster short-squeeze that sends the bears scrambling to cover some of their bets.

From a technical perspective, VEEV is currently trending above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently spiked sharply higher back above its 50-day moving average with decent upside volume flows. That move has now pushed shares of VEEV within range of triggering a major breakout trade above some key near-term overhead resistance levels post-earnings.

If you're bullish on VEEV, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $24.80 to $25.08 a share and then above $26.34 a share with high volume. Look for volume on that move that registers near or above its three-month average volume of 998,267 shares. If that breakout hits post-earnings, then VEEV will set up to re-test or possibly take out its next major overhead resistance levels at $29.06 to $34 a share.

http://www.thestreet.com/story/12857487/2/5-stocks-set-to-soar-on-bullish-earnings.html?puc=yahoo&cm_ven=YAHOO

27% of the 37.6 million float are SHORT. Amazing for this really great cloud tech company. Shorts must be punished!

Can anyone tell me the updated share structure and if it's changed since they went public?

Outstanding shares and authorized.

Could dilution be the cause of the drop in PPS?

Thanks I really would appreciate that.

"Veeva confirms loss of Genentech deal, says impact minimal05:10 PM ET • VEEVFollowing a column from SA author Suhail Partners reporting Veeva (VEEV) has lost Genentech as a cloud CRM software client, Veeva has confirmed its subscription agreement with Genentech expired last July.However, Veeva adds Genentech was at no point a top-20 customer over its last eight quarters, and doesn't think "the circumstances that led to the expiration of the Genentech Agreement are indicative of any trend among its customer base generally"

Alpha

"Pacific Crest said it is skeptical about reports that Veeva (VEEV) lost a client to Salesforce.com (CRM) given they have a non-compete and Salesforce.com has strong interest in the success of Veeva's platform."

I think Alpha says differently, I need to read the artcle again but u also can verify. Obviously Salesforce.com is Veev competitor and posed a threat and until it is confirmed one way or the other investors will were pulling out today. Especially since the slide we can't seem to manage.

What's going on here

Hummm,..Up $2.32 in premarket..Imagine that.

Gap down with this company doesn't concern me. When we get PR we'll gap right back up. Remember you only lose when you sell...I'm in for the long haul!

They are obviously biased, but quite a compelling case. Seem to have more of an issue with underwriters than veeeva biz.

Suhail Captial, a confirmed SHORT and full of sour grapes, is on a misson to kill this stock/company!

Note:"Veeva Systems: 'In The Land Of The Blind, The One-Eyed Man Is King'Dec 10 2013, 10:41 | by Suhail Capital about: VEEV"

I believe he is the one who supposedly thoroughly researched and gave various reasons why VEEV could not possibly beat the streets expectations for the most recent earnings/forecast report.

LOSER ! ! !

So I'm taking this as bad news? Well as long as it hits $45 soon, I'll be good! $$. Thanks for the info though . Good luck!

Why. #1 95% of revenue tied to Salesforce.com platform Force.com. Their contract expires in 2015. Salesforce is making moves in life science space above and beyond Veev. #2 Because of this dependence their IP is materially tied up with Force.com capability, functionality, etc--it is not easy to port the Veeva CRM to another open source platform for example if not practically impossible #3 CRM space getting fairly saturated--they will continue to grow but not at the pace they have fairly soon; #4 Veeva Vault is a key market segment to expand rapidly to keep justifying multiples and extremely high valuation--problems with Vault include A) regulated content management highly slow moving space--sales cycles long and complex even for a few hundred thousand dollar deal B) space is very competitive from large players like EMC (Documentum); Microsoft (SharePoint); Oracle (various content management capabilities); IBM (Websphere,FileNet, etc), Open Text (Livelink, et al), etc. to niche traditional players such as Qumas, CSC< MasterControl, NextDocs, Pilgrim, etc. to new horizontal open source/cloud upstarts that will move into this space including Box, DropBox and multiple others. In summary regulated content management space VERY competitive; conservative industry; long sales cycles; highly controlled processes, etc...Anything but a fast moving; high growth market. Moreover in life science space Documentum maintains near 100% penetration of market (it is the regulated ECM standard) and most compliance systems have eSignatures stored in these system. Even if Veeva gives away free many companies won't move--too much risk; too much compliance anxiety. A few will move to Veev and Veev will continue to expand in this space but the growth won't be at the rate over the next 24 months that the market expects #5 data management and other solutions could be compelling since they are accumulating a lot of information but they will from an architectural standpoint have to move OFF of Force to breakout here. Overall fantastic execution by leadership. Kudos to them but it is inevitable that sooner rather than later this company will move down to 4X to 5X their revenues.

Wow what happened here? Bad credibility for Cramer? "It's up $2, this is going higher today"

MM'S got a hold of this, probably thanks to Cramer's clue. Just hold on and buy more on the dips.

Veeva Announces Fiscal 2014 Third Quarter Results

Date : 12/05/2013 @ 4:02PM
Source : Business Wire
Stock : VEEVA SYSTEMS INC (VEEV)
Quote : $40.98 0.84 (2.09%) @ 8:00PM


Fiscal 2014 Third Quarter Results:

•Revenues: Total revenues for the third quarter were $55.0 million, up from $35.8 million one year ago, an increase of 54% year-over-year. Subscription services revenues were $38.9 million, up from $20.0 million one year ago, an increase of 95% year-over-year.

[....]

Financial Outlook:

Veeva is providing guidance for the fourth quarter of fiscal 2014 as follows:

• Total revenues between $57 and $58 million, an increase of 43% to 46% on a year-over-year basis. This implies full fiscal year revenues of approximately $204 to $205 million representing annual growth of 58% to 59%.

[....]

http://ih.advfn.com/p.php?pid=nmona&article=60289751

Congrats to everyone! Great numbers, future looks promising!

think we will be very happy

Fingers are crossed for earnings. Thinking good things to come.